title: Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony.
abstract: BACKGROUND
  Cutaneous leishmaniasis represents a difficult disease to manage in endemic areas. Systemic treatment is hampered by both expense and compliance. Side effects may play a major role in this aspect as well.
  
  
  METHODS
  The effectiveness of intralesional treatment of leishmaniasis was investigated. Seven hundred and ten patients were treated with injections of sodium stibogluconate intralesionally. The clinical diagnosis was confirmed by demonstrating the parasite in the smears obtained from the lesion. Fine insulin needle was used to infiltrate the lesion with sodium stibogluconate (0.5 to 1.0 mL).
  
  
  RESULTS
  Generally eight injections were sufficient, but some of the complicated lesions needed up to 24 injections. Sixty-two percent of patients were men. The majority of the study population (64%) were children below 15 years of age. The results showed that 72% of lesions healed completely, 23.9% showed some improvement, while 4.1% showed some deterioration. Lesions of the lips, cheeks, chin, and neck healed faster than lesions in other parts of the body. Side effects were mild and limited to pain at the site of the injection and hyperpigmentation in those who were treated by folk medicine.
  
  
  CONCLUSIONS
  Intralesional treatment is as effective as the standard systemic antimonials. It offers a less expensive alternative and a low side effects profile. Our findings confirmed the findings of earlier workers. It is recommended for treatment of cutaneous leishmaniasis in endemic areas.
authors.affiliation: Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
authors.forename: R M
authors.initials: RM
authors.lastname: Faris
authors.forename: J S
authors.initials: JS
authors.lastname: Jarallah
authors.forename: T A
authors.initials: TA
authors.lastname: Khoja
authors.forename: M J
authors.initials: MJ
authors.lastname: al-Yamani
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000967:Antimony Sodium Gluconate